Amicus Therapeutics Stock Forecast, Price & News

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last twelve months. There are currently 7 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Amicus Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FOLD, but not buy additional shares or sell existing shares.
View analyst ratings for Amicus Therapeutics or view top-rated stocks.

Wall Street analysts have given Amicus Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Amicus Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Amicus Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 1st 2021.
View our earnings forecast for Amicus Therapeutics.

Amicus Therapeutics will be holding an earnings conference call on Monday, March 1st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) announced its quarterly earnings data on Tuesday, November, 10th. The biopharmaceutical company reported ($0.23) EPS for the quarter, missing the Zacks' consensus estimate of ($0.20) by $0.03. The biopharmaceutical company had revenue of $67.44 million for the quarter, compared to analysts' expectations of $65.04 million. Amicus Therapeutics had a negative net margin of 120.18% and a negative trailing twelve-month return on equity of 73.81%.
View Amicus Therapeutics' earnings history.

Amicus Therapeutics' stock was trading at $8.05 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, FOLD shares have increased by 50.2% and is now trading at $12.09.
View which stocks have been most impacted by COVID-19.

Amicus Therapeutics updated its FY 2020 Pre-Market earnings guidance on Monday, January, 11th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $261-261 million, compared to the consensus revenue estimate of $259.24 million.

12 brokerages have issued 1 year price objectives for Amicus Therapeutics' shares. Their forecasts range from $12.50 to $31.00. On average, they expect Amicus Therapeutics' stock price to reach $20.79 in the next year. This suggests a possible upside of 72.0% from the stock's current price.
View analysts' price targets for Amicus Therapeutics or view top-rated stocks among Wall Street analysts.

21 employees have rated Amicus Therapeutics CEO John F. Crowley on Glassdoor.com. John F. Crowley has an approval rating of 48% among Amicus Therapeutics' employees. This puts John F. Crowley in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Amicus Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), Neurocrine Biosciences (NBIX) and United Therapeutics (UTHR).
View all of FOLD's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Exelixis (EXEL), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."

Amicus Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.40%), Morgan Stanley (4.89%), Janus Henderson Group PLC (4.32%), Avoro Capital Advisors LLC (3.45%), Lone Pine Capital LLC (2.56%) and Northern Trust Corp (1.24%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Burke W Whitman, Daphne Quimi, Ellen Rosenberg, Hung Do, Jay Barth, John F Crowley, Margaret G Mcglynn, Michael Raab and Samantha Prout.
View institutional ownership trends for Amicus Therapeutics.

FOLD stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Avoro Capital Advisors LLC, Clearbridge Investments LLC, Victory Capital Management Inc., Dimensional Fund Advisors LP, Panagora Asset Management Inc., Peregrine Capital Management LLC, and Rothschild & Co. Asset Management US Inc.. Company insiders that have sold Amicus Therapeutics company stock in the last year include Bradley L Campbell, Daphne Quimi, Ellen Rosenberg, Hung Do, Jay Barth, John F Crowley, Margaret G Mcglynn, Michael Raab, and Samantha Prout.
View insider buying and selling activity for Amicus Therapeutics or view top insider-selling stocks.

FOLD stock was acquired by a variety of institutional investors in the last quarter, including Lone Pine Capital LLC, Morgan Stanley, Canada Pension Plan Investment Board, BlackRock Inc., Price T Rowe Associates Inc. MD, Rice Hall James & Associates LLC, Cardan Capital Partners LLC, and Hood River Capital Management LLC.
View insider buying and selling activity for Amicus Therapeutics or or view top insider-buying stocks.

Shares of FOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of FOLD stock can currently be purchased for approximately $12.09.

Amicus Therapeutics has a market capitalization of $3.15 billion and generates $182.24 million in revenue each year. The biopharmaceutical company earns $-356,390,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis.

Amicus Therapeutics employs 584 workers across the globe.

The official website for Amicus Therapeutics is www.amicusrx.com.

Amicus Therapeutics is headquartered at 1 Cedar Brook Drive, Cranbury NJ, 08512.

Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The biopharmaceutical company can be reached via phone at 609-662-2000 or via email at [email protected]